← 홈

ADC

16개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 16개
ADCCHotBiologicstaleAdcendo ApSPhase 2

ADC (Antibody-drug conjugate, Antibody-drug conjugate (ADC))

Metastatic Soft Tissue Sarcoma; Unresectable Soft Tissue Sarcoma · Metastatic Soft Tissue Sarcoma

#MetastaticSoftTissueSarcoma#ADC#Phase2#인기#항체약물접합체+3
효능 ORR 31.2%임상시험 114상태 RECRUITING
ADCBiologicstaleFavrillederuxtecan for metastatic b…Phase 2

Antibody-Drug Conjugate Therapy (Antibody-Drug Conjugate Therapy)

Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 86%임상시험 58상태 RECRUITING
ADCBBiologicstaleADC TherapeuticsthatPhase 2

Anti-CD19 Antibody-Drug Conjugate (Loncastuximab Tesirine, Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate))

Diffuse Large B-Cell Lymphoma; High-grade B-cell Lymphoma (HGBCL) · CD19

#CD19#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 94.1%임상시험 48상태 RECRUITING
ADCBiologicstalePfizerPreclinical

Antibody Drug Conjugate Chemotherapeutic (Antibody Drug Conjugate Chemotherapeutic)

CD33 Positive Acute Myelogenous Leukemia · CD33

#CD33#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 51%임상시험 8상태 ACTIVE
ADCBiologicstaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin, anti-PD-1 antibody.)

Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma · PD-1

#PD-1#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 RECRUITING
ADCBiologicstaleCentral South UniversityPreclinical

Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate (Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate)

Sepsis (SMQ); Opportunistic Infections · Sepsis (SMQ)

#SepsisSMQ#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody)

Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma · PD-1

#PD-1#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleShanghai Fudan-Zhangjiang Bio-P…Phase 1

FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia (FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 ACTIVE
ADCBiologicstaleShanghai Fudan-Zhangjiang Bio-P…Phase 1

FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib (FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 ACTIVE
ADCBiologicstaleShengjing HospitalPhase 2

Next-generation Site-specific human epidermal growth factor receptor 2 (HER2, Next-generation Site-specific human epidermal growth factor receptor 2, Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788))

Breast Neoplasms · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleGilead SciencesPreclinical

ADC (Non-Investigational Antibody-Drug Conjugates, Non-Investigational Antibody-Drug Conjugates (ADC))

HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma · HER2

#HER2#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING
ADCBiologicstaleOxford BioTherapeutics LtdPhase 1

OBT076, a CD205-directed antibody-drug conjugate (OBT076, a CD205-directed antibody-drug conjugate)

Solid Tumor · CD20

#CD20#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleXijing HospitalPhase 2

RC48-ADC (Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent, Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent (RC48-ADC))

Breast Cancer; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 ACTIVE
ADCBiologicstaleGlaxoSmithKlinePhase 2

Unconjugated belantamab antibody (Unconjugated belantamab antibody)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleGlaxoSmithKlinePhase 2

belantamab mafodotin (Blenrep, GSK2857916, Unconjugated belantamab antibody and belantamab mafodotin)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleCSPC ZhongQi Pharmaceutical Tec…Phase 1

an antibody drug conjugate (an antibody drug conjugate)

Neoplasms · Neoplasms

#Neoplasms#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 31.2%임상시험 1상태 ACTIVE